The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection

Eur Respir J. 2015 Feb;45(2):571-4. doi: 10.1183/09031936.00157914.

Authors

Susanna Esposito¹, Luigi R Codecasa², Rosella Centis³

Affiliations

¹ Pediatric Highly Intensive Care Unit, Università degli Studi di Milano, Fondazione IRCCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy Both authors contributed equally.
² Reference Center for TB, Lombardy Region, Milan, Italy Both authors contributed equally.
³ World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri, Care and Research Institute, Tradate, Italy.

PMID: 25653275
DOI: 10.1183/09031936.00157914

No abstract available

Publication types

Letter
Comment

MeSH terms

Antitubercular Agents / administration & dosage*
Extensively Drug-Resistant Tuberculosis / drug therapy*
Humans
Male
Nitroimidazoles / administration & dosage*
Oxazoles / administration & dosage*

Substances

Antitubercular Agents
Nitroimidazoles
Oxazoles